APMR
Stories
-
Talazoparib plus enzalutamide versus placebo in metastatic APMR prostate cancer
The authors reported that 805 patients were enrolled in the TALAPRO-2 phase 3 trial, with 402 assigned to talazoparib plus enzalutamide and 403 to placebo plus enzalutamide. Median follow-up for radiographic progression-free survival was 24·9 months for the talazoparib group and 24·6 months for the placebo group.